Summary:
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Subjects With Obesity
Qualified Participants Must:
• Be 18 to 65 years old
• Have a BMI between 30 and 40
• Be generally healthy (not taking any medication)
• Be avaliable for a 10 day/9 night stay with 9 outpatient visits
• women must have their falopian tubes removed OR have ovaries removed OR have a hysterectomy OR be post menopausal.